Dermapharm Holding SEFRA:DMP 87 PB Ratio is 3.10 as of Jun. 27, 2026, which is 44% below its 10-year median of 5.51. GuruFocus rates FRA:DMP with a GF Score™ of 87/100 and a GF Value™ of €39.11 (Modestly Overvalued). The stock has 9 warning signs investors should review. Among 922 Drug Manufacturers companies, Dermapharm Holding SE ranks worse than 70.72% on this metric.
The historical rank and industry rank for Dermapharm Holding SE's PB Ratio or its related term are showing as below:
FRA:DMP'
s PB Ratio Range Over the Past 10 Years
Min: 2.68 Med: 5.51 Max: 19.43
Current: 3.1
During the past 13 years, Dermapharm Holding SE's highest PB Ratio was 19.43. The lowest was 2.68. And the median was 5.51.
FRA:DMP's PB Ratio is ranked worse than 70.72% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.825
vs FRA:DMP: 3.10
During the past 12 months, Dermapharm Holding SE's average Book Value Per Share Growth Rate was 25.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 9.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 13.50% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 33.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Dermapharm Holding SE was 83.20% per year. The lowest was 6.70% per year. And the median was 24.70% per year.
Back to Basics: PB Ratio
Dermapharm Holding SE (FRA:DMP) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Dermapharm Holding SE's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dermapharm Holding SE PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dermapharm Holding SE's PB Ratio distribution charts can be found below:
* The bar in red indicates where Dermapharm Holding SE's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Dermapharm Holding SE (FRA:DMP) has a PB Ratio of 3.10 as of Jun. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Dermapharm Holding SE and its competitors. This is 44% below median its historical median of 5.51. Over the past decade, Dermapharm Holding SE's PB Ratio has ranged from 2.68 to 19.43. According to the industry distribution chart, Dermapharm Holding SE ranks #652 out of 922 companies in the Drug Manufacturers industry, placing it in the top 70.7%.
Is Dermapharm Holding SE's PB Ratio too high?
Dermapharm Holding SE's current PB Ratio of 3.10 is 44% below median its 10-year median of 5.51. Over the past 10 years, this metric has ranged from a low of 2.68 to a high of 19.43. The Drug Manufacturers industry median PB Ratio is 1.83. Dermapharm Holding SE's value of 3.10 is 69.9% above this industry median. Based on the distribution chart, Dermapharm Holding SE ranks #652 out of 922 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Dermapharm Holding SE has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dermapharm Holding SE's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Dermapharm Holding SE ranks #652 out of 922 companies for PB Ratio. This places Dermapharm Holding SE in the lower half of its industry. The industry median PB Ratio is 1.83. Dermapharm Holding SE's value of 3.10 is 69.9% above this benchmark. Historically, Dermapharm Holding SE's own PB Ratio has ranged from 2.68 to 19.43 over the past decade. While the company's 10-year median is 5.51 vs. the industry median of 1.83, Dermapharm Holding SE has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.83, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dermapharm Holding SE's current PB Ratio of 3.10 is 69.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Dermapharm Holding SE and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dermapharm Holding SE's current PB Ratio is 3.10, which is 44% below median its own 10-year median of 5.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dermapharm Holding SE stock overvalued right now?
Based on GuruFocus' analysis, Dermapharm Holding SE (FRA:DMP) is currently considered Modestly Overvalued. The stock's GF Value™ is €39.11, compared to a current price of €46.25 — trading 18.3% above its estimated fair value. The current PB Ratio is 3.10, which is 44% below median its 10-year median of 5.51 and 69.9% above the Drug Manufacturers industry median of 1.83. Dermapharm Holding SE's overall GF Score™ is 87/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Dermapharm Holding SE (FRA:DMP), the current PB Ratio is 3.10 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dermapharm Holding SE (FRA:DMP) Overvalued in 2026?
Based on GuruFocus' analysis, Dermapharm Holding SE stock appears to be overvalued.
The current stock price of €46.25 is trading 18.3% above its estimated GF Value™ of €39.11.
GuruFocus considers Dermapharm Holding SE to be Modestly Overvalued.
Key valuation signals for FRA:DMP:
PB Ratio: 3.10 (44% below median its 10-year median of 5.51)
GF Value™: €39.11 vs. price of €46.25 (18.3% above fair value)
Industry Position: 69.9% above the Drug Manufacturers median (#652 of 922)
No single metric tells the full story. See the FRA:DMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.
87GF Score
Get the complete analysis for FRA:DMP
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:DMP has been successfully added to your 
